Send us a textWhat does the FDA jurisdiction for LDTs mean for the labs? Do they need to worry? How do they need to change the way they operate?In this episode, I talk with Dr. Thomas Nifong, a clinical pathologist and VP of CDX operations at Acrovan Therapeutics, about the recent FDA ruling on laboratory-developed tests (LDTs) issued on May 6th, 2024. We discuss the implications of considering LDTs as medical devices, requiring regulation, and explore the authority of FDA versus CLIA. The co...
Podden och tillhörande omslagsbild på den här sidan tillhör Aleksandra Zuraw, DVM, PhD. Innehållet i podden är skapat av Aleksandra Zuraw, DVM, PhD och inte av, eller tillsammans med, Poddtoppen.
